We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CHM market cap is 5.96M. The company's latest EPS is AUD -0.0147 and P/E is -0.68.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 0 | 2.62M | 4.51M | 9.61M |
| Operating Income | -64k | -14.85M | -14.57M | -24.98M | -11.03M |
| Net Income | -64k | -15.11M | -15.9M | -25.92M | -12.53M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 0 | 36.51M | 34.88M | 22.38M | 15.27M |
| Total Liabilities | 64k | 11.37M | 9.17M | 16.72M | 12.8M |
| Total Equity | -64k | 25.13M | 25.71M | 5.66M | 2.47M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -34k | -8.84M | -13.15M | -16.31M | -7.54M |
| Investing | N/A | -5.3M | -577k | -112k | N/A |
| Financing | 34k | 36.54M | 9.54M | 253k | 8.26M |
| Market Cap | 5.96M |
| Price to Earnings Ratio | -0.68 |
| Price to Sales Ratio | 0.88 |
| Price to Cash Ratio | 2.78 |
| Price to Book Ratio | 3.45 |
| Dividend Yield | - |
| Shares Outstanding | 851.79M |
| Average Volume (1 week) | 5.23M |
| Average Volume (1 Month) | 5.3M |
| 52 Week Change | -74.07% |
| 52 Week High | 0.043 |
| 52 Week Low | 0.006 |
| Spread (Intraday) | 0 (14.29%) |
| Company Name | Chimeric Therapeutics Limited |
| Address |
c/- the cfo solution melbourne, victoria 3053 |
| Website | https://www.chimerictherapeutics.com |
| Industry | noncomml resh organizations (8733) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
